Treatment of acute myelogenous leukemia with outpatient azacitidine-Reference-Cited by-同舟云学术

Treatment of acute myelogenous leukemia with outpatient azacitidine

Published:2006 Issue:8 Volume:107 Page:1839-1843
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Sudan Nimit,Rossetti James M.,Shadduck Richard K.,Latsko Joan,Lech John A.,Kaplan Robert B.,Kennedy Margaret,Gryn Jeffrey F.,Faroun Yacoub,Lister John

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference17 articles.

1. Acute Myeloid Leukemia

2. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.

3. Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

4. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine.

5. Correlation between Hypomethylation of DNA and Expression of Globin Genes in Friend Erythroleukemia Cells

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review on regulation of DNA methylation during post-myocardial infarction;Frontiers in Pharmacology;2024-02-13

2. Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective;Cancers;2022-06-25

3. Epigenetic Modulating Chemicals Significantly Affect the Virulence and Genetic Characteristics of the Bacterial Plant Pathogen Xanthomonas campestris pv. campestris;Genes;2021-05-25

4. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients;Blood Advances;2020-11-10

5. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States;Blood Advances;2020-05-20